摘要
目的观察二至柴芍散治疗甲亢性肝损害的临床疗效。方法从183例甲亢患者中筛选符合中、西医诊断标准的患者68例,采用随机数字表法抽取对照组和治疗组各34例,对照组予以甲巯咪唑联合多烯磷脂酰胆碱治疗,治疗组予以二至柴芍散联合甲巯咪唑治疗,疗程均为12周,观察治疗前后肝功能[丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天冬氨酸氨基转移酶(aspartate aminotransferase,AST)、总胆红素(total bilirubin,TBIL)、碱性磷酸酶(alkline phosphatase,ALP)、谷氨酰转移酶(gama glutamyl transferase,γ-GT)],甲状腺功能[游离三碘甲腺原氨酸(free triiodothyronine,FT3)、游离甲状腺素(free thyroxine,FT4)、促甲状腺激素(thyroid stimulating hormone,TSH)]及中医证候积分的变化。结果两组患者治疗后血清ALT、AST、TBIL、ALP、γ-GT含量均低于治疗前(P<0.05),治疗组患者血清ALT、AST、TBIL、ALP、γ-GT含量低于对照组(P<0.05);两组患者治疗后血清FT3、FT4均低于治疗前(P<0.05),TSH均高于治疗前(P<0.05),治疗组血清FT3、FT4、TSH变化值均大于对照组(P<0.05);两组患者治疗后中医证候评分均低于治疗前(P<0.05),治疗组中医证候评分低于对照组(P<0.05);两组患者临床疗效分布比较,差异无统计学意义(P>0.05)。结论二至柴芍散治疗甲亢性肝损害的临床疗效显著,无明显不良反应。
Objective To investigate the clinical effect thyroid liver damage. Methods A total of 68 patients were selected from 183 patients with hyperthyroidism of Erzhi Chaishao Powder in the treatment of hyperwho met the Chinese and Western diagnostic criteria and divided into control group and treatment group Results Both groups had significantly reduced serum levels of ALT, AST, TBⅡ, ALP, and γ-GT after treatment （P〈0.05）, and the treatment group had significantly lower levels than the control group （P〈0.05）. Both groups had significantly reduced serum levels of FT3 and FT4 and a significantly increased level of TSH after treatment （P〈0.05）, and the treatment group had significantly better improvements in the serum levels of FT3, FT4, and TSH than the control group （P〈0.05）. After treatment, both groups had significantly reduced TCM syndrome scores （P〈0.05）, and the treatment group had a significantly lower TCM syndrome score than the control group （P〈0.05）. There was no significant difference in the distribution of clinical outcomes between the two groups （P〈0.05）. Conclusion Erzhi Chaishao Powder has a significant clinical effect in the treatment of hyperthyroid liver damage with few adverse effects.
作者
张莉
刘怀珍
孟海雷
刘妙珠
ZHANG Li LIU Huai-zhen MENG Hai-lei LIU Miao-zhu(Anhui University of Chinese Medicine, Anhui Hefei 230012, China The First A f filiated Hospital of Anhui University of Chinese Medicine, Anhui Hefei 230031, China Taihe Hospital of Traditional Chinese Medicine, Anhui Taihe 236600, China)
出处
《安徽中医药大学学报》
2017年第2期10-14,共5页
Journal of Anhui University of Chinese Medicine
基金
安徽省卫生计生委中医药科研计划课题(2016zy12)
关键词
二至柴芍散
甲亢性肝损害
甲巯咪唑
Erzhi Chaishao Powder
Hyperthyroid liver damage
Methimazole
